How big is Agenus, Inc.?

As of Jun 18, Agenus, Inc. has a market capitalization of 131.05 million, with net sales of 99.53 million and a net profit of -195.19 million over the last four quarters. Shareholder's funds are reported at -326.38 million, and total assets amount to 226.27 million.

As of Jun 18, Agenus, Inc. has a market capitalization of 131.05 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 99.53 million, while the sum of net profit for the same period is -195.19 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -326.38 million, and total assets amount to 226.27 million.

What does Agenus, Inc. do?

Agenus, Inc. is an immuno-oncology company developing therapies to harness the immune system against cancer, with a market cap of $131.05 million and recent net sales of $24 million. The company reported a net loss of $26 million for the quarter ending March 2025.

Overview: <BR>Agenus, Inc. is an immuno-oncology company focused on developing therapies that engage the body's immune system to combat cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 24 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 131.05 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: 57.81% <BR>Price to Book: -0.38<BR><BR>Contact Details: <BR>Address: 3 Forbes Rd, LEXINGTON MA: 02421-7305 <BR>Tel: 1 781 6744400 <BR>Fax: 1 781 6744200 <BR>Website: http://agenusbio.com/

Who are in the management team of Agenus, Inc.?

As of March 2022, the management team of Agenus, Inc. includes Dr. Garo Armen (Chairman, CEO, Co-Founder), Mr. Timothy Wright (Lead Independent Director), Mr. Paul Clark, Ms. Susan Hirsch, Mr. Brian Corvese, and Dr. Allison Jeynes-Ellis (all Directors).

As of March 2022, the management team of Agenus, Inc. includes Dr. Garo Armen, who serves as the Chairman of the Board, Chief Executive Officer, and Co-Founder. Other members of the management team are Mr. Timothy Wright, the Lead Independent Director; Mr. Paul Clark, a Director; Ms. Susan Hirsch, a Director; Mr. Brian Corvese, an Independent Director; and Dr. Allison Jeynes-Ellis, also an Independent Director.

Should I buy, sell or hold Agenus, Inc.?

Is Agenus, Inc. overvalued or undervalued?

As of November 8, 2022, Agenus, Inc. is considered overvalued and has a risky valuation grade due to troubling financial ratios and significant underperformance compared to the S&P 500, with a 3-year return of -90.09% and a 5-year return of -95.52%.

As of 8 November 2022, the valuation grade for Agenus, Inc. has moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued, particularly given its troubling financial ratios, including a Price to Book Value of -0.48, an EV to EBIT of -4.84, and an EV to EBITDA of -5.54. These figures suggest significant financial distress compared to its peers, such as AnaptysBio, Inc. with an EV to EBITDA of -8.2275 and Entrada Therapeutics, Inc. at 1.6353, both of which are also classified as risky but show relatively better metrics.<BR><BR>In terms of stock performance, Agenus has underperformed against the S&P 500 across multiple time frames, with a staggering 3-year return of -90.09% compared to the S&P's 70.41%, and a 5-year return of -95.52% versus 96.61% for the index. This stark contrast reinforces the notion that Agenus is currently overvalued in the market.

Is Agenus, Inc. technically bullish or bearish?

As of September 3, 2025, Agenus, Inc. shows a mildly bullish technical trend with a year-to-date return of 66.06%, outperforming the S&P 500's 12.22%, but has underperformed over the past year with a return of -24.79% compared to the S&P 500's 17.14%.

As of 3 September 2025, the technical trend for Agenus, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are mildly bearish, creating a mixed signal. The monthly MACD and KST are mildly bullish, suggesting some positive momentum over a longer time frame. Overall, the technical stance is mildly bullish, driven primarily by the daily moving averages and monthly indicators.<BR><BR>In terms of performance, the stock has returned 66.06% year-to-date, significantly outperforming the S&P 500's 12.22%, but has underperformed over the past year with a return of -24.79% compared to the S&P 500's 17.14%.